Physician profile
Michael Nader
NPI 1851520613
$491.46
in general payments reported to CMS, 2019-2025
16 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.18 · 2022: $17.57 · 2023: $84.05 · 2024: $128 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.10 | 2023-2025 | |
| Astellas Pharma US INC | $62.88 | 2025 | Veozah |
| Allergan, INC. | $43.18 | 2020 | |
| Ironshore Pharmaceuticals INC. | $38.85 | 2023 | Jornay Pm |
| Exact Sciences Corporation | $29.62 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $27.49 | 2025 | |
| Novo Nordisk INC | $23.79 | 2024 | Wegovy |
| Rgh Enterprises LLC | $22.00 | 2025 | |
| Edwards Lifesciences Corporation | $21.65 | 2025 | Sapien 3 Ultra Resilia |
| Hologic Sales and Service, LLC | $20.12 | 2024 | Aptima |
| Sanofi Pasteur INC. | $17.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.94 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $15.96 | 2024 | Shingrix, Arexvy |
| Cranial Technologies, INC | $15.27 | 2024 | Doc Band |
| Astrazeneca Pharmaceuticals Lp | $15.01 | 2025 | Airsupra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.03 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.